Researchers undertook this interim analysis of an ongoing phase 1–2 open-label trial, KEYNOTE-051, to not only establish the recommended phase 2 dose of pembrolizumab but also to verify its safety as well as antitumour activity in advanced paediatric cancer.
Archive | Clinical Trials
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): Interim analysis of an open-label, single-arm, phase 1–2 trial
Posted in Melanoma News, Health Professionals, Clinical Trials
No Significant Benefit Demonstrated with Nivolumab/Ipilimumab Versus Nivolumab Alone in Advanced Melanoma
The combination of nivolumab (Opdivo) with ipilimumab (Yervoy) showed no statistically significant benefit in patients with stage IIIB/C/D or stage IV (no evidence of disease) melanoma compared with nivolumab alone in the phase III CheckMate 915 study, missing the co-primary endpoint of recurrence-free survival (RFS) in patients with
Posted in Melanoma News, Health Professionals, Clinical Trials
Whole-Brain Radiation Therapy vs Observation After Local Treatment of Melanoma Brain Metastases
In a phase III trial reported in the Journal of Clinical Oncology, Hong et al found that adjuvant whole-brain radiotherapy (WBRT) was not associated with a significant benefit in distant intracranial control vs observation after local treatment of patients with one to three melanoma brain metastases.
Posted in Melanoma News, Health Professionals, Clinical Trials
TKI Combination vs Monotherapy for Advanced Melanoma and the Risk for CV Adverse Events
Risks of high-grade arterial hypertension and high-grade reduction in left ventricular ejection fraction (LVEF) are increased for patients with advanced melanoma treated with a combination of BRAF and MEK inhibitors compared with those treated with BRAF inhibitor alone, according to study results published in JAMA Open Network.
Posted in Melanoma News, Health Professionals, Clinical Trials
